Showing 1561-1570 of 1635 results for "".
- Survey: Physicians Generate an Average of $2.4 Million a Year Per Hospitalhttps://modernod.com/news/survey-physicians-generate-an-average-of-2-4-million-a-year-per-hospital/2479591/While physicians are key providers of medical care at the nation’s hospitals, a new survey confirms they also are major drivers of hospital revenue. According to the survey, physicians generate an average $2,378,727 per year in net revenue on behalf of their af
- Oyster Point Raises $93 Million to Support the Clinical Development of Novel Treatment for Dry Eye Diseasehttps://modernod.com/news/oyster-point-raises-93-million-to-support-the-clinical-development-of-novel-treatment-for-dry-eye-disease/2476261/Oyster Point Pharma announced a $93 million Series B financing to support the development of its product portfolio for dry eye disease, explore new treatment areas, and add key talent. The company’s lead product candidates, OC-01 and OC-02, are delivered via an ocular surface-sparing nasal
- MacuLogix Relocates to Larger Headquarters in Harrisburg, Pennsylvania to Accommodate Growthhttps://modernod.com/news/maculogix-relocates-to-larger-headquarters-in-harrisburg-pennsylvania-to-accommodate-growth/2476286/MacuLogix relocated its headquarters from Middletown, PA, to Harrisburg as the company has grown from 12 to 65 employees in the past 3 years, including 25 home office employees supporting its national field-based sale
- UnitedHealthcare Vision Plans Rank Highest in Customer Satisfaction in J.D. Power Reporthttps://modernod.com/news/unitedhealthcare-vision-plans-rank-highest-in-customer-satisfaction-in-j-d-power-report/2476287/UnitedHealthcare Vision plans tied for highest in customer satisfaction among the nation’s vision carriers, according to the J.D. Power 2018 Vision Plan Satisfaction Report. This marks the fifth time in 6 years that UnitedHealthcare Vision has earned the highest ranking among vision plans.
- Diabetes Eye Exam Frequency in US Is ‘Alarmingly Low’https://modernod.com/news/diabetes-eye-exam-frequency-in-us-is-alarmingly-low/2476288/The frequency of eye exams among insured patients with type 1 and type 2 diabetes in the United States is “alarmingly low,” new research indicates, as reported in Medscape. Findings from an analysis of nationwide IBM Wa
- Heidelberg OCT2 Module Successfully Installed at the International Space Stationhttps://modernod.com/news/heidelberg-oct2-module-successfully-installed-at-the-international-space-station/2476295/Heidelberg Engineering announced that its Spectralis imaging platform with the company’s next-generation OCT2 Module has been successfully installed at the International Space Station (ISS) and is now fully operational. NASA launched the Spectralis with OCT2 Module to the ISS aboard the An
- Optical and Ophthalmology Cloud Solutions Provider KIDE Systems Becomes Topcon Healthcare Solutions EMEAhttps://modernod.com/news/optical-and-ophthalmology-cloud-solutions-provider-kide-systems-becomes-topcon-healthcare-solutions-emea/2476307/Following Topcon Healthcare Solutions’ acquisition of KIDE Systems in April 2018, KIDE Systems announced that it will take on the branding of its parent company Topcon Healthcare Solutions, part of Topcon Corporation. The brand change includes the change of KIDE System’s corporate name to Topcon
- Regeneron Q4 Earnings & Sales Beat on Strong Eylea Saleshttps://modernod.com/news/regeneron-q4-earnings-sales-beat-on-strong-eylea-sales/2476314/Regeneron Pharmaceuticals delivered impressive results in the fourth quarter of 2018 wherein both earnings and sales beat estimates, according to a Nasdaq report. Shares ar
- China’s NMPA Accepts NDA for IBI-305, a Biosimilar Product Candidate of Bevacizumab (Avastin)https://modernod.com/news/chinas-nmpa-accepts-nda-for-ibi-305-a-biosimilar-product-candidate-of-bevacizumab-avastin/2479596/Innovent Biologics announced that the National Medical Products Administration (NMPA) has accepted its new drug application (NDA) for a biosimilar product candidate of bevacizumab (Avastin). This NDA by Innovent is the third that has been accepted by the NMPA following Tyvyt (sintilimab injectio
- Nicox Announces FDA Acceptance of Investigational NDA for NCX 4251 Phase 2 Trial in Blepharitishttps://modernod.com/news/nicox-announces-fda-acceptance-of-investigational-nda-for-ncx-4251-phase-2-trial-in-blepharitis/2479597/Nicox SA announced that the FDA has completed its review of the company’s investigational new drug (IND) application for NCX 4251, a novel patented ophthalmic suspension of fluticasone propionate nanocrystals, being developed as the fi